You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Pertuzumab

Showing 26 - 50 of 355
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Boston, Ann Arbor (drug, procedure, radiation)

Active, not recruiting
Has Results
  • Breast Cancer
  • Boston, Massachusetts
  • +2 more
May 2, 2022

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer Trial (KN026, HB1801, Pertuzumab)

Not yet recruiting
  • First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
  • (no location specified)
Apr 20, 2023

HER2-positive Breast Cancer Trial in Philadelphia (Atezolizumab, Paclitaxel, Trastuzumab)

Suspended
  • HER2-positive Breast Cancer
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jul 5, 2022

Breast Cancer Trial in Guandong (pegylated liposomal doxorubicin (PLD), cyclophosphamide (C), trastuzumab (H))

Recruiting
  • Breast Cancer
  • pegylated liposomal doxorubicin (PLD)
  • +5 more
  • Guandong, Guangdong, China
    Sunyat-sen Memorial Hospital
Feb 17, 2022

Breast Tumors Trial in Mönchengladbach (drug, diagnostic test, procedure)

Active, not recruiting
  • Breast Neoplasms
  • Perjeta Injectable Product
  • +13 more
  • Mönchengladbach, Germany
    Evangelisches Krankenhaus Bethesda Mönchengladbach
Oct 4, 2022

HER2-positive Early Breast Cancer Trial in China (drug, procedure, radiation)

Active, not recruiting
  • HER2-positive Early Breast Cancer
  • Pertuzumab IV
  • +8 more
  • Beijing, China
  • +17 more
Nov 21, 2022

Metastatic Breast Cancer Trial in Spain (Ipatasertib, Trastuzumab, Pertuzumab)

Recruiting
  • Metastatic Breast Cancer
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022

Metastatic Breast Cancer Trial in Baltimore (Trastuzumab plus Pertuzumab, Hormonal Therapy with Anastrozole and Fulvestrant,

Terminated
Has Results
  • Metastatic Breast Cancer
  • Trastuzumab plus Pertuzumab
  • +2 more
  • Baltimore, Maryland
    University of Maryland Marlene & Stewart Greenebaum Cancer Cente
May 4, 2022

HER2-positive Breast Cancer Trial in Shenyang (ARX788, Pyrotinib maleate, Trastuzumab)

Recruiting
  • HER2-positive Breast Cancer
  • Shenyang, Liaoning, China
    Shengjing Hospital affiliated to China Medical University
Jun 21, 2022

Breast Cancer Trial in United States (Positron emission tomography (PET), Trastuzumab, Pertuzumab)

Active, not recruiting
Has Results
  • Breast Cancer
  • Positron emission tomography (PET)
  • +2 more
  • Birmingham, Alabama
  • +9 more
Jan 20, 2023

Breast Tumors Trial in Barcelona (Cyclophosphamide, Trastuzumab, Pertuzumab)

Recruiting
  • Breast Neoplasms
  • Barcelona, Spain
  • +1 more
May 31, 2022

HER-2 Positive Breast Cancer Trial in Tianjin (TCbHP VS ddEC-THP)

Recruiting
  • HER-2 Positive Breast Cancer
  • TCbHP VS ddEC-THP
  • Tianjin, Tianjin, China
    Breast Oncology, Tianjin Medical University Cancer Institute and
May 15, 2023

Breast Cancer Trial in Helsinki (Pertuzumab, Trastuzumab)

Active, not recruiting
  • Breast Cancer
  • Helsinki, Finland
    Helsinki University Central Hospital
Mar 15, 2022

Breast Tumor Female Trial in Beijing (CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou))

Recruiting
  • Breast Neoplasm Female
  • CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
  • Beijing, Beijing, China
  • +1 more
Jul 31, 2023

Breast Cancer Invasive Trial in Shanghai (Pyrotinib, Trastuzumab, Pertuzumab)

Active, not recruiting
  • Breast Cancer Invasive
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Mar 28, 2022

HER2-positive Metastatic Breast Cancer, CNS Metastases Trial in Chicago, Boston (ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB)

Active, not recruiting
  • HER2-positive Metastatic Breast Cancer
  • Central Nervous System Metastases
  • Chicago, Illinois
  • +1 more
Mar 14, 2022

Breast Cancer Trial in Moscow, Omsk, Saint Petersburg (BCD-178, Perjeta)

Recruiting
  • Breast Cancer
  • Moscow, Russian Federation
  • +2 more
Apr 5, 2023

Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and

Recruiting
  • HER2-positive Metastatic Breast Cancer
  • +2 more
  • trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy
  • Beijing, Beijing, China
    Ruyan Zhang
Dec 27, 2021

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma Trial in United States

Recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +2 more
  • Los Angeles, California
  • +4 more
Jul 19, 2022

Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin +

Recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Docetaxel + Carboplatin + Trastuzumab + Pertuzumab
  • (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jul 24, 2022

Early Breast Cancer, Locally Advanced Breast Cancer, Inflammatory Breast Cancer Trial in Canada, Mexico, Spain (drug, procedure,

Recruiting
  • Early Breast Cancer
  • +2 more
  • Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
  • +6 more
  • Buenos Aires, Argentina
  • +29 more
Jan 31, 2023

Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)

Not yet recruiting
  • Breast Neoplasms
  • Guangzhou, Gangdong, China
    Sun-yat sen university cancer center
Jul 30, 2023

HER2-positive Early Breast Cancer Trial in Germany (Trastuzumab deruxtecan, Standard-of-Care)

Not yet recruiting
  • HER2-positive Early Breast Cancer
  • Munich, Bavaria, Germany
  • +11 more
Jan 19, 2023

HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer Trial in Boston, Nashville (T-DM1, Pertuzumab, Excision of

Active, not recruiting
Has Results
  • HER-2 Positive Breast Cancer
  • +3 more
  • Boston, Massachusetts
  • +3 more
Mar 4, 2022

Breast Cancer Trial in Boston, Milford, South Weymouth (Paclitaxel, Trastuzumab, Pertuzumab)

Active, not recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +4 more
Feb 4, 2022